Future perspective and clinical applicability of the combined use of plasma phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive Decline and Mild Cognitive Impairment.

Humans tau Proteins / blood Cognitive Dysfunction / blood Male Female Neurofilament Proteins / blood Aged Biomarkers / blood Phosphorylation Alzheimer Disease / blood Middle Aged Amyloid beta-Peptides / blood
Alzheimer’s Disease Mild Cognitive Impairment NfL Plasma biomarkers Subjective Cognitive Decline p-tau181

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 May 2024
Historique:
received: 01 03 2024
accepted: 08 05 2024
medline: 18 5 2024
pubmed: 18 5 2024
entrez: 17 5 2024
Statut: epublish

Résumé

We aimed to assess diagnostic accuracy of plasma p-tau181 and NfL separately and in combination in discriminating Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) patients carrying Alzheimer's Disease (AD) pathology from non-carriers; to propose a flowchart for the interpretation of the results of plasma p-tau181 and NfL. We included 43 SCD, 41 MCI and 21 AD-demented (AD-d) patients, who underwent plasma p-tau181 and NfL analysis. Twenty-eight SCD, 41 MCI and 21 AD-d patients underwent CSF biomarkers analysis (Aβ1-42, Aβ1-42/1-40, p-tau, t-tau) and were classified as carriers of AD pathology (AP+) it they were A+/T+ , or non-carriers (AP-) when they were A-, A+/T-/N-, or A+/T-/N+ according to the A/T(N) system. Plasma p-tau181 and NfL separately showed a good accuracy (AUC = 0.88), while the combined model (NfL + p-tau181) showed an excellent accuracy (AUC = 0.92) in discriminating AP+ from AP- patients. Plasma p-tau181 and NfL results were moderately concordant (Coehn's k = 0.50, p < 0.001). Based on a logistic regression model, we estimated the risk of AD pathology considering the two biomarkers: 10.91% if both p-tau181 and NfL were negative; 41.10 and 76.49% if only one biomarker was positive (respectively p-tau18 and NfL); 94.88% if both p-tau181 and NfL were positive. Considering the moderate concordance and the risk of presenting an underlying AD pathology according to the positivity of plasma p-tau181 and NfL, we proposed a flow chart to guide the combined use of plasma p-tau181 and NfL and the interpretation of biomarker results to detect AD pathology.

Identifiants

DOI: 10.1038/s41598-024-61655-6 PMID: 38760423
pubmed: 38760423
doi: 10.1038/s41598-024-61655-6
pii: 10.1038/s41598-024-61655-6
doi:

Substances chimiques

neurofilament protein L 0
MAPT protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

11307

Subventions

Organisme : Regione Toscana
ID : D19G22000640002

Informations de copyright

© 2024. The Author(s).

Références

Jack, C. R. et al. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alz. Dement. 14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018 (2018).
doi: 10.1016/j.jalz.2018.02.018
Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alz. Dement. 7(3), 280–292. https://doi.org/10.1016/j.jalz.2011.03.003 (2011).
doi: 10.1016/j.jalz.2011.03.003
Lewczuk, P. et al. Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol. Aging 25(3), 273–281. https://doi.org/10.1016/S0197-4580(03)00086-1 (2004).
doi: 10.1016/S0197-4580(03)00086-1 pubmed: 15123331
Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: A prospective cohort study. Lancet Neurol. 11(8), 669–678. https://doi.org/10.1016/S1474-4422(12)70142-4 (2012).
doi: 10.1016/S1474-4422(12)70142-4 pubmed: 22749065
Mueller, A. et al. Tau PET imaging with 18F-PI-2620 in patients with Alzheimer disease and healthy controls: A first-in-humans study. J. Nucl. Med. 61(6), 911–919. https://doi.org/10.2967/jnumed.119.236224 (2020).
doi: 10.2967/jnumed.119.236224 pubmed: 31712323 pmcid: 7262222
Mattsson, N. et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302(4), 385–393. https://doi.org/10.1001/jama.2009.1064 (2009).
doi: 10.1001/jama.2009.1064 pubmed: 19622817
Ebenau, J. L. et al. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. Neurology 95(1), e46–e58. https://doi.org/10.1212/WNL.0000000000009724 (2020).
doi: 10.1212/WNL.0000000000009724 pubmed: 32522798 pmcid: 7371376
Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer’s disease: Towards clinical implementation. Lancet Neurol. 21(1), 66–77. https://doi.org/10.1016/S1474-4422(21)00361-6 (2022).
doi: 10.1016/S1474-4422(21)00361-6 pubmed: 34838239
Lantero Rodriguez, J. et al. Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 140(3), 267–278. https://doi.org/10.1007/s00401-020-02195-x (2020).
doi: 10.1007/s00401-020-02195-x pubmed: 32720099 pmcid: 7423866
Moscoso, A. et al. Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum. Brain 144(1), 325–339. https://doi.org/10.1093/brain/awaa399 (2021).
doi: 10.1093/brain/awaa399 pubmed: 33257949
Giacomucci, G. et al. Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer’s disease pathology in subjective cognitive decline and mild cognitive impairment. J. Neurol. Sci. 453, 120805. https://doi.org/10.1016/j.jns.2023.120805 (2023).
doi: 10.1016/j.jns.2023.120805 pubmed: 37716237
Mazzeo, S. et al. Plasma neurofilament light chain predicts Alzheimer’s disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study. Eur. J. Neurol. https://doi.org/10.1111/ene.16089 (2023).
doi: 10.1111/ene.16089 pubmed: 37797300
Mazzeo, S. et al. The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment. Neurol. Sci. https://doi.org/10.1007/s10072-023-07065-4 (2023).
doi: 10.1007/s10072-023-07065-4 pubmed: 37723371 pmcid: 10857957
Ebenau, J. L. et al. Association of CSF, plasma, and imaging markers of neurodegeneration with clinical progression in people with subjective cognitive decline. Neurology 98(13), e1315–e1326. https://doi.org/10.1212/WNL.0000000000200035 (2022).
doi: 10.1212/WNL.0000000000200035 pubmed: 35110378 pmcid: 8967429
Jucker, M. & Walker, L. C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501(7465), 45–51. https://doi.org/10.1038/nature12481 (2013).
doi: 10.1038/nature12481 pubmed: 24005412 pmcid: 3963807
Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alz. Dement. 7(3), 270–279. https://doi.org/10.1016/j.jalz.2011.03.008 (2011).
doi: 10.1016/j.jalz.2011.03.008
Jessen, F. et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alz. Dement. 10(6), 844–852. https://doi.org/10.1016/j.jalz.2014.01.001 (2014).
doi: 10.1016/j.jalz.2014.01.001
Mazzeo, S. et al. Predicting the evolution of subjective cognitive decline to Alzheimer’s disease with machine learning: The preview study protocol. BMC Neurol. 23, 1. https://doi.org/10.1186/s12883-023-03347-8 (2023).
doi: 10.1186/s12883-023-03347-8
Alcolea, D. et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer’s disease on lumipulse-pubmed. Ann. Clin. Transl. Neurol. 6(9), 1815–1824 (2019).
doi: 10.1002/acn3.50873 pubmed: 31464088 pmcid: 6764494
Giacomucci, G. et al. Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in subjective cognitive decline and mild cognitive impairment. J. Neurol. https://doi.org/10.1007/s00415-022-11055-5 (2022).
doi: 10.1007/s00415-022-11055-5 pubmed: 35288777 pmcid: 9293849
Bessi, V. et al. PER2 C111G polymorphism, cognitive reserve and cognition in subjective cognitive decline and mild cognitive impairment: A 10-year follow-up study. Eur. J. Neurol. 28(1), 56–65. https://doi.org/10.1111/ene.14518 (2021).
doi: 10.1111/ene.14518 pubmed: 32896064
Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28(6), 595–599. https://doi.org/10.1038/nbt.1641 (2010).
doi: 10.1038/nbt.1641 pubmed: 20495550 pmcid: 2919230
Karikari, T. K. et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative. Mol. Psychiatr. 26(2), 429–442. https://doi.org/10.1038/s41380-020-00923-z (2021).
doi: 10.1038/s41380-020-00923-z
Janelidze, S. et al. Plasma P-tau181 in Alzheimer’s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat. Med. 26(3), 379–386. https://doi.org/10.1038/s41591-020-0755-1 (2020).
doi: 10.1038/s41591-020-0755-1 pubmed: 32123385
Shen, X. N. et al. Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status. Transl. Psychiatr. 11(1), 585. https://doi.org/10.1038/s41398-021-01709-9 (2021).
doi: 10.1038/s41398-021-01709-9
Barba, L. et al. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatr. 94(1), 83–86. https://doi.org/10.1136/jnnp-2022-329124 (2023).
doi: 10.1136/jnnp-2022-329124
Huang, Y., Li, Y., Xie, F. & Guo, Q. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients. CNS Neurosci. Ther. 28(12), 2195–2205. https://doi.org/10.1111/cns.13962 (2022).
doi: 10.1111/cns.13962 pubmed: 36074638 pmcid: 9627371
Gaetani, L. et al. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatr. 90(8), 870–881. https://doi.org/10.1136/jnnp-2018-320106 (2019).
doi: 10.1136/jnnp-2018-320106
Gaetani, L. & Parnetti, L. NfL as analogue of C-reactive protein in neurologic diseases: Instructions for use. Neurology 98(22), 911–912. https://doi.org/10.1212/WNL.0000000000200752 (2022).
doi: 10.1212/WNL.0000000000200752 pubmed: 35418454
Sarto, J. et al. Diagnostic performance and clinical applicability of blood-based biomarkers in a prospective memory clinic cohort. Neurology 100(8), e860–e873. https://doi.org/10.1212/WNL.0000000000201597 (2023).
doi: 10.1212/WNL.0000000000201597 pubmed: 36450604 pmcid: 9984216
Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain 146(4), 1592–1601. https://doi.org/10.1093/brain/awac333 (2023).
doi: 10.1093/brain/awac333 pubmed: 36087307
Mattsson-Carlgren, N. et al. Prediction of longitudinal cognitive decline in preclinical alzheimer disease using plasma biomarkers. JAMA Neurol. 80(4), 360–369. https://doi.org/10.1001/jamaneurol.2022.5272 (2023).
doi: 10.1001/jamaneurol.2022.5272 pubmed: 36745413 pmcid: 10087054
Chételat, G. et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. Lancet Neurol. 19(11), 951–962. https://doi.org/10.1016/S1474-4422(20)30314-8 (2020).
doi: 10.1016/S1474-4422(20)30314-8 pubmed: 33098804
Perra, D. et al. Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with lewy bodies. Brain Commun. 3(2), fcab045. https://doi.org/10.1093/braincomms/fcab045 (2021).
doi: 10.1093/braincomms/fcab045 pubmed: 33870192 pmcid: 8042247
de Wilde, A. et al. Disclosure of amyloid positron emission tomography results to individuals without dementia: A systematic review. Alz. Res. Ther. 10(1), 72. https://doi.org/10.1186/s13195-018-0398-3 (2018).
doi: 10.1186/s13195-018-0398-3
Dubois, B. et al. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer’s disease (INSIGHT-preAD): A longitudinal observational study. Lancet Neurol. 17(4), 335–346. https://doi.org/10.1016/S1474-4422(18)30029-2 (2018).
doi: 10.1016/S1474-4422(18)30029-2 pubmed: 29500152
Hampel, H. et al. Designing the next-generation clinical care pathway for Alzheimer’s disease. Nat. Aging 2(8), 692–703. https://doi.org/10.1038/s43587-022-00269-x (2022).
doi: 10.1038/s43587-022-00269-x pubmed: 37118137 pmcid: 10148953

Auteurs

Giulia Giacomucci (G)

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla, 3, 50134, Florence, Italy.

Salvatore Mazzeo (S)

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla, 3, 50134, Florence, Italy.
Vita-Salute San Raffaele University, Milan, Italy.
IRCCS Policlinico San Donato, San Donato Milanese, Italy.

Assunta Ingannato (A)

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla, 3, 50134, Florence, Italy.

Chiara Crucitti (C)

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla, 3, 50134, Florence, Italy.

Silvia Bagnoli (S)

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla, 3, 50134, Florence, Italy.

Sonia Padiglioni (S)

Regional Referral Centre for Relational Criticalities - Tuscany Region, University of Florence, Florence, Italy.
Research and Innovation Centre for Dementia-CRIDEM, AOU Careggi, Florence, Italy.

Lucrezia Romano (L)

University of Florence, Florence, Italy.

Giulia Galdo (G)

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla, 3, 50134, Florence, Italy.

Filippo Emiliani (F)

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla, 3, 50134, Florence, Italy.

Daniele Frigerio (D)

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla, 3, 50134, Florence, Italy.

Camilla Ferrari (C)

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla, 3, 50134, Florence, Italy.

Valentina Moschini (V)

SOD Neurologia I, Dipartimento Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi, Florence, Italy.

Carmen Morinelli (C)

SOD Neurologia I, Dipartimento Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi, Florence, Italy.

Antonella Notarelli (A)

Research and Innovation Centre for Dementia-CRIDEM, AOU Careggi, Florence, Italy.
SOD Neurologia I, Dipartimento Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi, Florence, Italy.

Sandro Sorbi (S)

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla, 3, 50134, Florence, Italy.
IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.

Benedetta Nacmias (B)

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla, 3, 50134, Florence, Italy. benedetta.nacmias@unifi.it.
IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy. benedetta.nacmias@unifi.it.

Valentina Bessi (V)

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla, 3, 50134, Florence, Italy.
Research and Innovation Centre for Dementia-CRIDEM, AOU Careggi, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Future perspective and clinical applicability...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines associées aux microtubules › Protéines tau › Future perspective and clinical applicability...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › Future perspective and clinical applicability...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines neurofilamenteuses › Future perspective and clinical applicability...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Future perspective and clinical applicability...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Future perspective and clinical applicability...
questionsmedicales.fr › Métabolisme › Phosphorylation › Future perspective and clinical applicability...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Future perspective and clinical applicability...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Future perspective and clinical applicability...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Peptides bêta-amyloïdes › Future perspective and clinical applicability...